232 related articles for article (PubMed ID: 9137215)
1. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
[TBL] [Abstract][Full Text] [Related]
2. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure.
Adamopoulos S; Parissis J; Karatzas D; Kroupis C; Georgiadis M; Karavolias G; Paraskevaidis J; Koniavitou K; Coats AJ; Kremastinos DT
J Am Coll Cardiol; 2002 Feb; 39(4):653-63. PubMed ID: 11849865
[TBL] [Abstract][Full Text] [Related]
3. Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure.
Kinugawa T; Kato M; Yamamoto K; Hisatome I; Nohara R
Int Heart J; 2012; 53(3):182-6. PubMed ID: 22790687
[TBL] [Abstract][Full Text] [Related]
4. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
[TBL] [Abstract][Full Text] [Related]
5. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD.
Yasuda N; Gotoh K; Minatoguchi S; Asano K; Nishigaki K; Nomura M; Ohno A; Watanabe M; Sano H; Kumada H; Sawa T; Fujiwara H
Respir Med; 1998 Aug; 92(8):993-9. PubMed ID: 9893764
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy.
Adamopoulos S; Parissis JT; Georgiadis M; Karatzas D; Paraskevaidis J; Kroupis C; Karavolias G; Koniavitou K; Kremastinos DT
Am Heart J; 2002 Aug; 144(2):359-64. PubMed ID: 12177657
[TBL] [Abstract][Full Text] [Related]
7. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy.
Zen K; Irie H; Doue T; Takamiya M; Yamano T; Sawada T; Azuma A; Matsubara H
Int Heart J; 2005 Mar; 46(2):231-44. PubMed ID: 15876807
[TBL] [Abstract][Full Text] [Related]
8. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
9. [Role of soluble Fas ligand in myocardial remodeling, severity and outcomes of chronic heart failure].
Teplyakov AT; Berezikova EN; Shilov SN; Grakova EV; Torim YY; Efremov AV; Popova AA; Pustovetova MG; Sabirova AY; Kopyeva KV
Ter Arkh; 2016; 88(9):10-16. PubMed ID: 27735908
[TBL] [Abstract][Full Text] [Related]
10. Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system.
Setsuta K; Seino Y; Ogawa T; Ohtsuka T; Seimiya K; Takano T
Circ J; 2004 Aug; 68(8):747-50. PubMed ID: 15277733
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
12. [Effect of Astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure].
Zhang JG; Yang N; He H; Wei GH; Gao DS; Wang XL; Wang XZ; Song GY
Chin J Integr Med; 2005 Sep; 11(3):187-90. PubMed ID: 16181532
[TBL] [Abstract][Full Text] [Related]
13. Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure.
Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Kinoshita M
J Card Fail; 2001 Dec; 7(4):322-8. PubMed ID: 11782855
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction.
Ohtsuka T; Hamada M; Sasaki O; Suzuki M; Hara Y; Shigematsu Y; Ohtani T; Honda T; Hiwada K
Coron Artery Dis; 1999 Jun; 10(4):221-5. PubMed ID: 10376200
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy.
Parissis JT; Adamopoulos S; Karatzas D; Paraskevaidis J; Livanis E; Kremastinos D
Eur J Cardiovasc Prev Rehabil; 2005 Apr; 12(2):164-8. PubMed ID: 15785303
[TBL] [Abstract][Full Text] [Related]
16. Proinflammatory cytokines, soluble Fas receptor, nitric oxide and angiotensin converting enzyme in congestive heart failure.
El Sherif WT; El Tooney LF; Meki AR; Abdel Moneim A
Egypt J Immunol; 2005; 12(1):39-48. PubMed ID: 16734138
[TBL] [Abstract][Full Text] [Related]
17. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients.
Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH
Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151
[TBL] [Abstract][Full Text] [Related]
18. The value of plasma levels of tumor necrosis factor-alpha and interleukin-6 in predicting the severity and prognosis in patients with congestive heart failure.
Pan JP; Liu TY; Chiang SC; Lin YK; Chou CY; Chan WL; Lai ST
J Chin Med Assoc; 2004 May; 67(5):222-8. PubMed ID: 15357108
[TBL] [Abstract][Full Text] [Related]
19. [The application of Apo-1/Fas to evaluate apoptosis of myocardial cells in patients with congestive heart failure].
Li Z; Jiao B; Qian H; Qian X; Mo B
Zhonghua Nei Ke Za Zhi; 1999 Mar; 38(3):168-70. PubMed ID: 11798644
[TBL] [Abstract][Full Text] [Related]
20. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
